Novel Insights from Clinical Practice
Corneal Myofibroma (Keloid) in a Young Patient with Neurofibromatosis Type 2Zimmermann L.a · Reinhard T.a · Lange C.a · Heegaard S.b · Auw-Haedrich C.a
aEye Center, Albert-Ludwigs-University, Freiburg, Germany; bPathology Department, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
We present a 27-year-old male patient with neurofibromatosis type 2 (NF2), facial palsy, and lagophthalmos following acoustic neuroma removal and an impressing vascularized corneal tumor, which was excised. Histology showed a fibrous tumor with small vessels, and immunohistochemistry was positive for vimentin and negative for smooth muscle actin, S100, and GFAP. We assume a corneal myofibroma (keloid), which in this case rather represents a reactive lesion. This entity has not been described before in NF2 or in facial palsy-associated lagophthalmos in general.
© 2017 S. Karger AG, Basel
- Evans DGR: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
- Parry DM, Eldridge R, Kaiser-Kupfer MI, et al: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-461.
- McLaughlin ME, Pepin SM, Maccollin M, et al: Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007;125:389-394.
- Bouzas EA, Freidlin V, Parry DM, et al: Lens opacities in neurofibromatosis 2: further significant correlations. Br J Ophthalmol 1993;77:354-357.
- Holbach LM, Font RL, Shivitz IA, Jones DB: Bilateral keloid-like myofibroblastic proliferations of the cornea in children. Ophthalmology 1990;97:1188-1193.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.